Engineering a Nanotherapeutic for Metastatic Prostate Cancer with Bone-targeting Specificity

Simple item page
dc.creatorLampe, Jana B.
dc.creatorDesai, Priyanka
dc.creatorRanjan, Amalendu
dc.creatorVishwanatha, Jamboor
dc.date.accessioned2021-04-30T14:26:07Z
dc.date.available2021-04-30T14:26:07Z
dc.date.issued2021
dc.description.abstractProstate cancer (PCA) derived bone metastases account for 90% of metastatic tumors with a five-year overall survival rate of 29.5%. Our objective is to develop a clinically feasible nano-delivery system targeting bone-metastatic sites to prolong overall survival and improve quality of life. The purpose of this project is to engineer a cabazitaxel-loaded, poly-lactic(co-glycolic) acid (PLGA) nanoparticle (NP) with alendronate (ALN) coating to target and treat metastatic bone lesions. We hypothesize that a bone targeted nano-delivery system will ameliorate bone lesions and trigger tumor cell apoptosis. Methods: NPs were formulated using a water-in-oil-in solvent evaporation method. NPs were prepared by sonicating 50 mg/ml PLGA in dichloromethane (DCM), 5% polyvinyl alcohol (PVA), and Bis(sulfosuccinimydyl)suberate (BS3) linker. Later, ALN was conjugated to the NP. Results: Our average NP size was around 200 nm in diameter with a Zeta Potential (ZP) of – 28 mV. Our drug loading capacity (DL) was 12.4% and encapsulation efficiency was 25.3%. The IC50 value is 10 μM. NPs have also shown to be easily taken up by cancer cells. Conclusion: We have shown that our PLGA NPs have an optimal size, PDI, ZP, DL%, and EE%, which indicates that we have developed a NP that will function as a nanotherapeutic for bone metastatic PCa. The next steps will include spheroid cultures and in vivo studies.
dc.description.sponsorshipResearch reported in this publication was supported by the National Institute On Minority Health And Health Disparities of the National Institutes of Health under Award Number S21MD012472. The content is solely the responsibility of the authors and does
dc.identifier.urihttps://hdl.handle.net/20.500.12503/30491
dc.language.isoen
dc.titleEngineering a Nanotherapeutic for Metastatic Prostate Cancer with Bone-targeting Specificity
dc.typeposter
dc.type.materialtext

Files

Collections

Cancer